Matching articles for "pregabalin"
Issue 1747 · February 2, 2026
Risks of Tramadol and Gabapentin Use for Pain

Tramadol ( Ultram , and others) and gabapentin ( Neurontin , and others) are increasingly being prescribed for treatment of chronic pain despite reports of serious adverse events associated with their use.…

Med Lett Drugs Ther. 2026 Feb 2; 68(1747):22-4 doi:10.58347/tml.2026.1747d
Tramadol ( Ultram , and others) and gabapentin ( Neurontin , and others) are increasingly being prescribed for treatment of chronic pain despite reports of serious adverse events associated with their use. Both drugs are touted as safer and less addictive than strong opioids, but supporting evidence is lacking.
Issue 1746 · January 19, 2026
Sublingual Cyclobenzaprine (Tonmya) for Fibromyalgia

The FDA has approved Tonmya (Tonix), a sublingual tablet formulation of the skeletal muscle relaxant cyclobenzaprine, for treatment of fibromyalgia in adults. Cyclobenzaprine is available in immediate-release…

Med Lett Drugs Ther. 2026 Jan 19; 68(1746):9-10 doi:10.58347/tml.2026.1746a
The FDA has approved Tonmya (Tonix), a sublingual tablet formulation of the skeletal muscle relaxant cyclobenzaprine, for treatment of fibromyalgia in adults. Cyclobenzaprine is available in immediate-release tablets and extended-release capsules for short-term treatment of muscle spasms and has been used off-label for treatment of fibromyalgia.
Issue 1708 · August 5, 2024
Comparison Table: Some Oral Antiseizure Medications (online only)

View the Comparison Table: Some Oral Antiseizure Medications

Med Lett Drugs Ther. 2024 Aug 5; 66(1708):e133-40 doi:10.58347/tml.2024.1708b
View the Comparison Table: Some Oral Antiseizure Medications
Issue 1708 · August 5, 2024
Drugs for Epilepsy

When used for the appropriate seizure type, antiseizure medications (ASMs) are roughly equivalent in efficacy. In addition to the seizure type, the choice of drug is usually based on factors such as ease of…

Med Lett Drugs Ther. 2024 Aug 5; 66(1708):121-8 doi:10.58347/tml.2024.1708a
When used for the appropriate seizure type, antiseizure medications (ASMs) are roughly equivalent in efficacy. In addition to the seizure type, the choice of drug is usually based on factors such as ease of use, spectrum of activity, adverse effects, interactions with other drugs, presence of comorbid conditions, suitability for elderly persons and those with childbearing potential, and cost. Treatment should begin with a single drug, increasing the dosage gradually until seizures are controlled or adverse effects become unacceptable. If seizures persist, expert clinicians generally try at least one and sometimes a second alternative drug as monotherapy before considering use of two drugs at the same time.
Issue 1697 · March 4, 2024
Drugs for Menopausal Symptoms

The primary symptoms of menopause are genitourinary and vasomotor. The genitourinary syndrome of menopause (GSM) includes symptoms such as burning, irritation, dryness, dyspareunia, dysuria, and recurrent…

Med Lett Drugs Ther. 2024 Mar 4; 66(1697):33-8 doi:10.58347/tml.2024.1697a
The primary symptoms of menopause are genitourinary and vasomotor. The genitourinary syndrome of menopause (GSM) includes symptoms such as burning, irritation, dryness, dyspareunia, dysuria, and recurrent urinary tract infection. Vasomotor symptoms (VMS; hot flashes, night sweats) often disrupt sleep.
Issue 1686 · October 2, 2023 Free
Addendum: Gabapentinoids and Renal Impairment

A nephrologist and longtime reader of The Medical Letter wrote us to say that our recent article entitled Drugs for Anxiety Disorders should have said more about the need for dosage adjustment of gabapentin (…

Med Lett Drugs Ther. 2023 Oct 2; 65(1686):160 doi:10.58347/tml.2023.1686e
A nephrologist and longtime reader of The Medical Letter wrote us to say that our recent article entitled Drugs for Anxiety Disorders should have said more about the need for dosage adjustment of gabapentin ( Neurontin , and others) and pregabalin ( Lyrica , and others) in patients with renal impairment. Both drugs, he pointed out, are exclusively renally eliminated and can accumulate in patients with diminished renal function. Symptoms, which can include altered mental status, may develop so slowly that neither the patient nor the practitioner connect them to the drug. The resolution of adverse effects upon discontinuation can be slow.
Issue 1682 · August 7, 2023
Drugs for Anxiety Disorders

Anxiety disorders (generalized anxiety disorder, panic disorder, social anxiety disorder, and various phobias) are the most common form of psychiatric illness. They can be treated effectively with cognitive…

Med Lett Drugs Ther. 2023 Aug 7; 65(1682):121-8 doi:10.58347/tml.2023.1682a
Anxiety disorders (generalized anxiety disorder, panic disorder, social anxiety disorder, and various phobias) are the most common form of psychiatric illness. They can be treated effectively with cognitive behavioral therapy (CBT) and/or pharmacotherapy.
Issue 1679 · June 26, 2023
Fezolinetant (Veozah) for Menopausal Vasomotor Symptoms

Fezolinetant ( Veozah – Astellas), a first-in-class neurokinin 3 (NK3) receptor antagonist, has been approved by the FDA for treatment of moderate to severe vasomotor symptoms (VMS) due to menopause. It is…

Med Lett Drugs Ther. 2023 Jun 26; 65(1679):97-9 doi:10.58347/tml.2023.1679a
Fezolinetant ( Veozah – Astellas), a first-in-class neurokinin 3 (NK3) receptor antagonist, has been approved by the FDA for treatment of moderate to severe vasomotor symptoms (VMS) due to menopause. It is the second nonhormonal treatment to be approved in the US for this indication; a low-dose formulation of the selective serotonin reuptake inhibitor (SSRI) paroxetine mesylate (Brisdelle) was approved in 2013.
Issue 1667 · January 9, 2023
Drugs for Chronic Insomnia

Cognitive behavioral therapy for insomnia (CBT-I) is recommended for initial treatment of chronic insomnia. CBT-I includes stimulus control, sleep education and hygiene, sleep restriction, relaxation training,…

Med Lett Drugs Ther. 2023 Jan 9; 65(1667):1-6 doi:10.58347/tml.2023.1667a
Cognitive behavioral therapy for insomnia (CBT-I) is recommended for initial treatment of chronic insomnia. CBT-I includes stimulus control, sleep education and hygiene, sleep restriction, relaxation training, and cognitive therapy. When CBT-I alone is not effective, pharmacologic treatment should be added.
Issue 1645 · March 7, 2022
Nonopioid Drugs for Pain

Nonopioid drugs can be used in the treatment of many nociceptive and neuropathic pain conditions. For severe pain, especially severe chronic cancer pain, use of opioids may be necessary. Noninvasive…

Med Lett Drugs Ther. 2022 Mar 7; 64(1645):33-40
Nonopioid drugs can be used in the treatment of many nociceptive and neuropathic pain conditions. For severe pain, especially severe chronic cancer pain, use of opioids may be necessary. Noninvasive nonpharmacologic treatments, including physical and psychological therapies, have been shown to improve pain and function in patients with some common chronic pain conditions and are unlikely to cause serious harms. A multimodal approach to analgesic therapy can increase pain control while reducing opioid use and adverse effects.
Issue 1643 · February 7, 2022
Difelikefalin (Korsuva) for Chronic Kidney Disease-Associated Pruritus

Difelikefalin ( Korsuva – Vifor), an IV kappa opioid receptor (KOR) agonist, has been approved by the FDA for treatment of moderate to severe pruritus associated with chronic kidney disease (CKD) in adults…

Med Lett Drugs Ther. 2022 Feb 7; 64(1643):18-9
Difelikefalin ( Korsuva – Vifor), an IV kappa opioid receptor (KOR) agonist, has been approved by the FDA for treatment of moderate to severe pruritus associated with chronic kidney disease (CKD) in adults on hemodialysis. It is the first drug to be approved for this indication and the first KOR agonist to become available in the US. Difelikefalin has not been studied in patients on peritoneal dialysis.
Issue 1604 · August 10, 2020
Drugs for Menopausal Symptoms

The primary symptoms of menopause are genitourinary (genitourinary syndrome of menopause; GSM) and vasomotor (VMS). Vulvovaginal atrophy can cause vaginal burning, irritation and dryness, dyspareunia, and…

Med Lett Drugs Ther. 2020 Aug 10; 62(1604):124-8
The primary symptoms of menopause are genitourinary (genitourinary syndrome of menopause; GSM) and vasomotor (VMS). Vulvovaginal atrophy can cause vaginal burning, irritation and dryness, dyspareunia, and dysuria, and increase the risk of urinary tract infections. Vasomotor symptoms ("hot flashes") cause daytime discomfort and night sweats that may disrupt sleep. Hormone therapy is the most effective treatment for both genitourinary and vasomotor symptoms.
Issue 1599 · June 1, 2020 Free
In Brief: Respiratory Depression with Gabapentinoids

The FDA has required new warnings in the labels of gabapentin ( Neurontin , and others) and pregabalin ( Lyrica , Lyrica CR , and generics) about the risk of life-threatening or fatal respiratory depression in…

Med Lett Drugs Ther. 2020 Jun 1; 62(1599):81
The FDA has required new warnings in the labels of gabapentin ( Neurontin , and others) and pregabalin ( Lyrica , Lyrica CR , and generics) about the risk of life-threatening or fatal respiratory depression in patients with respiratory risk factors. Respiratory risk factors include chronic obstructive pulmonary disease (COPD) and concurrent use of opioids or other CNS depressants. Elderly patients are also at increased risk.
Issue 1594 · March 23, 2020
Drugs for Irritable Bowel Syndrome

Irritable bowel syndrome (IBS) is a common disorder characterized by recurrent abdominal pain and altered bowel habits, often accompanied by bloating.IBS is classified according to the predominant bowel…

Med Lett Drugs Ther. 2020 Mar 23; 62(1594):41-8
Irritable bowel syndrome (IBS) is a common disorder characterized by recurrent abdominal pain and altered bowel habits, often accompanied by bloating.IBS is classified according to the predominant bowel symptom as IBS with constipation (IBS-C), IBS with diarrhea (IBS-D), mixed type (IBS-M), or unclassified (IBS-U). Alterations in the microbiome, stress responses, sensory and motor function of the gut, and host genetic factors may be contributing factors. Since the exact cause of IBS is unknown, the goal of treatment is symptom control.
Issue 1594 · March 23, 2020
Table: Safety of Drugs for IBS in Pregnancy and Lactation (online only)

View the Table: Safety of Drugs for IBS in Pregnancy and Lactation

Med Lett Drugs Ther. 2020 Mar 23; 62(1594):e48-9
View the Table: Safety of Drugs for IBS in Pregnancy and Lactation
Issue 1578 · August 12, 2019
Drugs for Anxiety Disorders

Anxiety disorders (generalized anxiety disorder, panic disorder, social anxiety disorder, and various phobias) are the most common form of psychiatric illness. They can be treated effectively with cognitive…

Med Lett Drugs Ther. 2019 Aug 12; 61(1578):121-6
Anxiety disorders (generalized anxiety disorder, panic disorder, social anxiety disorder, and various phobias) are the most common form of psychiatric illness. They can be treated effectively with cognitive behavioral therapy (CBT) and/or pharmacotherapy. Obsessive-compulsive disorder and posttraumatic stress disorder are now considered separate entities in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5); they can also be treated with CBT and many of the same drugs.
Issue 1568 · March 25, 2019
ZTlido - A New Lidocaine Patch for Postherpetic Neuralgia

A lidocaine 1.8% patch ( ZTlido – Scilex) has been approved by the FDA for treatment of pain associated with postherpetic neuralgia (PHN). A lidocaine 5% patch ( Lidoderm , and generics) was approved earlier…

Med Lett Drugs Ther. 2019 Mar 25; 61(1568):41-3
A lidocaine 1.8% patch ( ZTlido – Scilex) has been approved by the FDA for treatment of pain associated with postherpetic neuralgia (PHN). A lidocaine 5% patch ( Lidoderm , and generics) was approved earlier for the same indication and has been used off-label for treatment of other types of localized pain. Both of these patches are available only by prescription. Lidocaine 4% patches ( Aspercreme , IcyHot , and others) are available over the counter for back, neck, shoulder, and joint pain.
Issue 1566 · February 25, 2019
Oxybutynin for Hot Flashes in Women with Breast Cancer

Interim results of a double-blind, placebo-controlled trial suggest that off-label use of the anticholinergic drug oxybutynin may reduce the frequency and severity of hot flashes in women with breast cancer.…

Med Lett Drugs Ther. 2019 Feb 25; 61(1566):30-1
Interim results of a double-blind, placebo-controlled trial suggest that off-label use of the anticholinergic drug oxybutynin may reduce the frequency and severity of hot flashes in women with breast cancer. Extended-release oral oxybutynin ( Ditropan XL , and generics) has been shown to reduce the frequency and severity of hot flashes in healthy menopausal women.
Issue 1562 · December 17, 2018
Drugs for Chronic Insomnia

Cognitive behavioral therapy for insomnia (CBT-I) is recommended for initial treatment of chronic insomnia. Pharmacologic treatment should be used in addition to CBT-I when CBT-I alone is not effective.

Med Lett Drugs Ther. 2018 Dec 17; 60(1562):201-5
Cognitive behavioral therapy for insomnia (CBT-I) is recommended for initial treatment of chronic insomnia. Pharmacologic treatment should be used in addition to CBT-I when CBT-I alone is not effective.
Issue 1540 · February 12, 2018
Nonopioid Drugs for Pain

Nonopioid drugs can be used in the treatment of many nociceptive and neuropathic pain conditions. Use of opioids for pain will be reviewed in a future issue.

Med Lett Drugs Ther. 2018 Feb 12; 60(1540):24-32
Nonopioid drugs can be used in the treatment of many nociceptive and neuropathic pain conditions. Use of opioids for pain will be reviewed in a future issue.
Issue 1526 · July 31, 2017
Comparison Table: Some Oral Antiepileptic Drugs (online only)

View the Comparison Table: Some Oral Antiepileptic Drugs

Med Lett Drugs Ther. 2017 Jul 31; 59(1526):e130-6
View the Comparison Table: Some Oral Antiepileptic Drugs
Issue 1526 · July 31, 2017
Drugs for Epilepsy

Treatment of epilepsy should begin with a single antiepileptic drug (AED), increasing its dosage gradually until seizures are controlled or adverse effects become intolerable. If seizures persist, specialists…

Med Lett Drugs Ther. 2017 Jul 31; 59(1526):121-30
Treatment of epilepsy should begin with a single antiepileptic drug (AED), increasing its dosage gradually until seizures are controlled or adverse effects become intolerable. If seizures persist, specialists generally recommend trying at least one and sometimes a second alternative drug as monotherapy before considering use of two drugs concurrently. When used for the appropriate seizure type, AEDs are roughly equivalent in efficacy. Drug choice is usually based on factors such as ease of use, adverse effects, drug interactions, presence of comorbidities, and cost.
Issue 1472 · July 6, 2015
Drugs for Insomnia

Pharmacological treatment of insomnia includes prescription drugs, non-prescription medications, and "natural" remedies. Behavioral approaches such as cognitive behavioral therapy, which are not discussed…

Med Lett Drugs Ther. 2015 Jul 6; 57(1472):95-8
Pharmacological treatment of insomnia includes prescription drugs, non-prescription medications, and "natural" remedies. Behavioral approaches such as cognitive behavioral therapy, which are not discussed here, are also used. Pharmacologic treatment and behavioral therapy are often combined.
Issue 128 · April 1, 2013
Drugs for Pain

Pain can be acute or chronic. The two major types of chronic pain are nociceptive pain and neuropathic pain. Nociceptive pain can be treated with nonopioid analgesics or opioids. Neuropathic pain is less…

Treat Guidel Med Lett. 2013 Apr; 11(128):31-42
Pain can be acute or chronic. The two major types of chronic pain are nociceptive pain and neuropathic pain. Nociceptive pain can be treated with nonopioid analgesics or opioids. Neuropathic pain is less responsive to opioids and is often treated with adjuvant drugs such as antidepressants and antiepileptics. Combining different types of analgesics may provide an additive analgesic effect without increasing adverse effects.
Issue 126 · February 1, 2013
Drugs for Epilepsy

Treatment of epilepsy should begin with a single drug, increasing the dosage gradually until seizures are controlled or adverse effects become unacceptable. If seizures persist, expert clinicians generally…

Treat Guidel Med Lett. 2013 Feb; 11(126):9-18
Treatment of epilepsy should begin with a single drug, increasing the dosage gradually until seizures are controlled or adverse effects become unacceptable. If seizures persist, expert clinicians generally prescribe at least one and sometimes a second alternative drug as monotherapy before considering use of two drugs at the same time. When used for the appropriate seizure type, antiepileptic drugs are roughly equivalent in efficacy. The choice of drug is usually based on factors such as ease of use, adverse effects, interactions with other drugs, presence of comorbid conditions and cost.
Issue 1397 · August 20, 2012
Ezogabine (Potiga) for Epilepsy

The FDA has approved ezogabine (ee-ZOE-ga-been; Potiga – GSK/Valeant) for oral adjunctive treatment of partial-onset seizures in adults. Ezogabine is available in Europe as retigabine (Trobalt) .

Med Lett Drugs Ther. 2012 Aug 20; 54(1397):65-7
The FDA has approved ezogabine (ee-ZOE-ga-been; Potiga – GSK/Valeant) for oral adjunctive treatment of partial-onset seizures in adults. Ezogabine is available in Europe as retigabine (Trobalt) .
Issue 1365 · May 30, 2011
Capsaicin Patch (Qutenza) for Postherpetic Neuralgia

The FDA has approved a topical 8% patch formulation of capsaicin ( Qutenza – NeurogesX), available only by prescription, for local treatment of postherpetic neuralgia. Postherpetic neuralgia occurs after…

Med Lett Drugs Ther. 2011 May 30; 53(1365):42-3
The FDA has approved a topical 8% patch formulation of capsaicin ( Qutenza – NeurogesX), available only by prescription, for local treatment of postherpetic neuralgia. Postherpetic neuralgia occurs after herpes zoster in about one third of patients ≥60 years old and can persist for months or even years.
Issue 92 · April 1, 2010
Drugs for Pain

Pain can be acute or chronic. Chronic pain has been broadly classified into two types: nociceptive and neuropathic. Nociceptive pain can be treated with nonopioid analgesics or opioids. Neuropathic pain is…

Treat Guidel Med Lett. 2010 Apr; 8(92):25-34
Pain can be acute or chronic. Chronic pain has been broadly classified into two types: nociceptive and neuropathic. Nociceptive pain can be treated with nonopioid analgesics or opioids. Neuropathic pain is less responsive to opioids; adjuvant medicines such as antidepressants and anticonvulsants are often used to treat neuropathic pain. Combining different types of analgesics may provide an additive analgesic effect without increasing adverse effects.
Issue 1332 · February 22, 2010
Vigabatrin (Sabril) for Epilepsy

The FDA has approved vigabatrin (vye gá ba trin; Sabril – Lundbeck) for oral use as add-on therapy for complex partial seizures in adults who are refractory to several antiepileptic drugs and as monotherapy…

Med Lett Drugs Ther. 2010 Feb 22; 52(1332):14-6
The FDA has approved vigabatrin (vye gá ba trin; Sabril – Lundbeck) for oral use as add-on therapy for complex partial seizures in adults who are refractory to several antiepileptic drugs and as monotherapy for infantile spasms. Vigabatrin has been available in other countries for many years. Because of its potential for retinal toxicity, it will be available in the US only through a restricted distribution program called SHARE (Support, Help and Resources for Epilepsy). Prescribers and pharmacists distributing the drug must register, and patients must undergo visual field testing.
Issue 1315 · June 29, 2009
Lacosamide for Epilepsy

The FDA has approved lacosamide ( Vimpat - UCB Pharma) for oral or intravenous (IV) use as add-on therapy in adults with partial-onset seizures.

Med Lett Drugs Ther. 2009 Jun 29; 51(1315):50-2
The FDA has approved lacosamide ( Vimpat - UCB Pharma) for oral or intravenous (IV) use as add-on therapy in adults with partial-onset seizures.
Issue 1314 · June 15, 2009
Milnacipran (Savella) for Fibromyalgia

Milnacipran ( Savella - Forest), an oral selective serotonin and norepinephrine reuptake inhibitor (SNRI), is the third drug approved by the FDA for management of fibromyalgia. The 2 others are pregabalin, a…

Med Lett Drugs Ther. 2009 Jun 15; 51(1314):45-8
Milnacipran ( Savella - Forest), an oral selective serotonin and norepinephrine reuptake inhibitor (SNRI), is the third drug approved by the FDA for management of fibromyalgia. The 2 others are pregabalin, a gammaaminobutyric acid (GABA) analog also approved for treatment of diabetic neuropathy, post-herpetic neuralgia and epilepsy, and duloxetine, an SNRI also approved for treatment of depression, diabetic neuropathy and generalized anxiety disorder.
Issue 1301 · December 15, 2008 Free
Drugs That May Cause Psychiatric Symptoms

Many drugs can cause psychiatric symptoms, but a causal connection is often difficult to establish. Psychiatric symptoms that emerge during drug treatment could also be due to the underlying illness,…

Med Lett Drugs Ther. 2008 Dec 15; 50(1301):100-3
Many drugs can cause psychiatric symptoms, but a causal connection is often difficult to establish. Psychiatric symptoms that emerge during drug treatment could also be due to the underlying illness, previously unrecognized psychopathology, or psychosocial factors. The withdrawal of some drugs can cause symptoms such as anxiety, psychosis, delirium, agitation or depression. Click here to view the free full article.
Issue 1291 · July 28, 2008
Duloxetine (Cymbalta) for Fibromyalgia

Duloxetine ( Cymbalta - Lilly) is the second drug to be approved by the FDA for treatment of fibromyalgia. Pregabalin (Lyrica) , which is also approved for treatment of neuropathic pain and epilepsy, was the…

Med Lett Drugs Ther. 2008 Jul 28; 50(1291):57
Duloxetine ( Cymbalta - Lilly) is the second drug to be approved by the FDA for treatment of fibromyalgia. Pregabalin (Lyrica) , which is also approved for treatment of neuropathic pain and epilepsy, was the first. Duloxetine is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) that is already marketed for treatment of depression and diabetic neuropathy.
Issue 70 · June 1, 2008
Drugs for Epilepsy

Treatment of epilepsy should begin with a single drug, increasing the dosage gradually until seizures are controlled or adverse effects become unacceptable. If seizures continue and further dosage increases…

Treat Guidel Med Lett. 2008 Jun; 6(70):37-46
Treatment of epilepsy should begin with a single drug, increasing the dosage gradually until seizures are controlled or adverse effects become unacceptable. If seizures continue and further dosage increases appear inadvisable because of adverse effects, most Medical Letter consultants generally prescribe at least one and sometimes a second alternative drug as monotherapy before considering use of two drugs at the same time. Most antiepileptic drugs initially approved by the FDA only as adjunctive therapy for partial seizures may also be effective for other types of seizures and as monotherapy. Studies suggest that when used for the appropriate seizure type, antiepileptic drugs are roughly equivalent in efficacy. The choice of a drug is usually based on factors such as ease of use, adverse effects and cost.
Issue 1270 · September 24, 2007
Pregabalin (Lyrica) for Fibromyalgia

Pregabalin ( Lyrica - Pfizer) is the first drug approved by the FDA for management of fibromyalgia. When it was first marketed, pregabalin, which is structurally similar to gabapentin ( Neurontin , and…

Med Lett Drugs Ther. 2007 Sep 24; 49(1270):77-9
Pregabalin ( Lyrica - Pfizer) is the first drug approved by the FDA for management of fibromyalgia. When it was first marketed, pregabalin, which is structurally similar to gabapentin ( Neurontin , and others), was approved for treatment of neuropathic pain associated with postherpetic neuralgia and diabetic peripheral neuropathy and for adjunctive treatment of partial onset seizures in adults with epilepsy. It has also been prescribed off-label for other types of neuropathic pain such as sciatica.
Issue 39 · November 1, 2005
Drugs for Epilepsy

Treatment of epilepsy should begin with a single drug, increasing the dosage gradually until seizures are controlled or adverse effects become unacceptable. If seizures continue and further dosage increases…

Treat Guidel Med Lett. 2005 Nov; 3(39):75-82
Treatment of epilepsy should begin with a single drug, increasing the dosage gradually until seizures are controlled or adverse effects become unacceptable. If seizures continue and further dosage increases appear inadvisable because of adverse effects, most Medical Letter consultants generally prescribe at least one and sometimes a second alternative drug as monotherapy before considering use of two drugs at the same time. Most antiepileptic drugs initially approved by the FDA only as adjunctive therapy for partial seizures may also be effective for other types of seizures and as monotherapy.
Issue 1217 · September 12, 2005
Pregabalin (Lyrica) for Neuropathic Pain and Epilepsy

Pregabalin ( Lyrica - Pfizer), a structural analog of gamma-aminobutyric acid (GABA) similar to gabapentin ( Neurontin - Pfizer, and others), which recently became available generically, has been approved by…

Med Lett Drugs Ther. 2005 Sep 12; 47(1217):75-6
Pregabalin ( Lyrica - Pfizer), a structural analog of gamma-aminobutyric acid (GABA) similar to gabapentin ( Neurontin - Pfizer, and others), which recently became available generically, has been approved by the FDA for treatment of neuropathic pain associated with postherpetic neuralgia (PHN) and diabetic peripheral neuropathy (DPN), and for adjunctive treatment of partial onset seizures in adults with epilepsy.
Issue 1215 · August 15, 2005
Duloxetine (Cymbalta) for Diabetic Neuropathic Pain

Duloxetine hydrochloride ( Cymbalta - Lilly), a selective serotonin and norepinephrine reuptake inhibitor (SNRI) available for treatment of depression, has also been approved by the FDA for treatment of…

Med Lett Drugs Ther. 2005 Aug 15; 47(1215):67-8
Duloxetine hydrochloride ( Cymbalta - Lilly), a selective serotonin and norepinephrine reuptake inhibitor (SNRI) available for treatment of depression, has also been approved by the FDA for treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPN). Duloxetine is one of two drugs approved specifically for management of neuropathic pain due to diabetes; the other, pregabalin ( Lyrica - Pfizer), will be marketed soon and will be reviewed in the next issue of The Medical Letter .